Management of common but potentially serious and even fatal side effects of CAR-T cell therapies like cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) has come a long way since entering the market. Now, Gilead Sciences, Inc. is piloting a partnership with community oncology centers to do much of the clinical legwork, enabling patients to receive CAR-T therapy closer to home instead of having to travel to academic medical centers.
The Foster City, CA-based drug maker introduced the partnership with Tennessee Oncology in the first quarter
Key Takeaways
-
Gilead is piloting a program with Tennessee Oncology designed to bring CAR-T cell therapy into the community oncology practice setting.
-
Following apheresis at the hospital, patients receive lymphodepletion and infusion at the community oncology clinic and then can go to the hospital if they need inpatient care